Rac GTPase Inhibition in Chronic Myelogenous Leukemia
Rac GTPase Inhibition in Chronic Myelogenous Leukemia
批准号:
8235866
负责人:
Jose A Cancelas
金额:
$37.13万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-06 至 2014-02-28
关键词:
Acute leukemiaAdhesionsApoptosisBiochemicalCD34 geneCell Cycle ProgressionCell SurvivalCell physiologyCellsCessation of lifeChronic Myeloid LeukemiaChronic-Phase Myeloid LeukemiaDataDevelopmentDiseaseEventGene TargetingGrowthGuanosineGuanosine Triphosphate PhosphohydrolasesHealthHematopoietic stem cellsHomingIn VitroIndividualMaintenanceMalignant NeoplasmsMediatingModelingMolecularMolecular TargetMusMyelogenousMyeloproliferative diseasePathway interactionsPatientsPhenotypePhiladelphia ChromosomePhosphatidylinositolsPhosphotransferasesPlayProtein IsoformsProteinsProto-Oncogene Proteins c-aktRoleSTAT proteinSignal PathwaySignal TransductionStem cellsTyrosine Kinase Inhibitorbasebcr-abl Fusion Proteinscell transformationcombinatorialdosagefusion genehuman diseasein vivoin vivo Modelkinase inhibitorleukemialeukemic stem cellleukemogenesismetaplastic cell transformationmigrationnew therapeutic targetnovelprogenitorrac GTP-Binding Proteinsrac1 GTP-Binding Proteinretroviral transductionrhosmall molecule
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Rac GTPase inhibition in Chronic Myelogenous Leukemia. Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disease with deregulated expression of the fusion gene p210-BCR-ABL. P210-BCR-ABL is needed to initiate and maintain CML. Molecular targeting of p210-BCR-ABL by inhibiting the abl kinase activity can suppress growth and induces apoptosis of CML cells. However, Abl kinase inhibitors are not able to eradicate the disease and alternatives targeting signaling downstream of p210-BCR-ABL in HSC/P are required. Since dysregulated Rac activity has been implicated in cancer transformation (and we have previously shown the role of Rac1 and Rac2 Rho GTPases in regulating proliferation, stem cell localization and apoptosis of HSC/P), we hypothesize that full p210-BCR-ABL mediated transformation of hematopoietic stem cells requires Rac activity and that Rac GTPase isoforms play distinct roles in the initiation and/or maintenance of p210-BCR- ABL-induced leukemia. By taking advantage of gene-targeted mice lacking Rac1, Rac2 and Rac3 and a pharmacological approach in vitro and in vivo in murine and human disease, we have generated preliminary data to indicate that Rac proteins play an essential role in the leukemogenic effects of p210-BCR-ABL in vitro and in vivo. In Specific Aim 1, we will investigate the requirement of the Rho GTPases Rac1, Rac2 and Rac3, or combinations in vitro and in vivo in leukemia initiation and in cell transformation. We will also investigate the role of Rac effectors and downstream signals in leukemia initiation. In Specific Aim 2, we will analyze whether Rac (and specific Rac isoforms) play distinct or redundant roles in the maintenance of leukeminas induced by p210-BCR-ABL. Finally, we will analyze whether the downstream signals activated by Rac for leukemic maintenance are different from the ones required for initiation. The results obtained from this project will validate the potential role of Rac GTPases as novel molecular targets for CML and dissect out the signals induced by Rac activation required for leukemogenesis and potential new targets for leukemic therapy. PUBLIC HEALTH RELEVANCE: Chronic myelogenous leukemia is a disease caused by the expression of an abnormal protein called BCR/ABL. Rac GTPases are a group of proteins that act as molecular switches in the cells. We will analyze whether Rac GTPases are critical for the development of leukemias induced by BCR/ABL and analyze the specific mechanisms depending on Rac GTPases responsible for leukemia formation.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1111/j.1537-2995.2011.03378.x
发表时间:
2011-11
期刊:
Transfusion
影响因子:
2.9
作者:
[Cancelas JA]
通讯作者:
Cancelas JA
Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells.
Bmi1 将 CML B 淋巴祖细胞重新编程为 B-ALL 起始细胞。
DOI:
10.1182/blood-2011-06-359232
发表时间:
2012
期刊:
Blood
影响因子:
20.3
作者:
[Sengupta,Amitava, Ficker,AshleyM, Dunn,SusanK, Madhu,Malav, Cancelas,JoseA]
通讯作者:
Cancelas,JoseA
DOI:
10.1038/ncomms2645
发表时间:
2013
期刊:
Nature communications
影响因子:
16.6
作者:
[]
通讯作者:
DOI:
10.1007/978-1-61779-145-1_13
发表时间:
2011
期刊:
Methods in molecular biology (Clifton, N.J.)
影响因子:
--
作者:
[Cancelas, Jose A]
通讯作者:
Cancelas, Jose A
DOI:
10.1111/imr.12119
发表时间:
2013-11
期刊:
Immunological reviews
影响因子:
8.7
作者:
[Nayak RC, Chang KH, Vaitinadin NS, Cancelas JA]
通讯作者:
Cancelas JA
共 8 条
Mechanism of a novel approach for platelet cold storage
-
批准号:10494385
-
项目类别:
-
资助金额:$65.58万
-
财政年份:2022
-
负责人:Jose A Cancelas
-
依托单位:
Mechanism of a novel approach for platelet cold storage
-
批准号:10682608
-
项目类别:
-
资助金额:$60.74万
-
财政年份:2022
-
负责人:Jose A Cancelas
-
依托单位:
Gene Delivery Core
-
批准号:10673658
-
项目类别:
-
资助金额:$9.75万
-
财政年份:2021
-
负责人:Jose A Cancelas
-
依托单位:
Gene Delivery Core
-
批准号:10201889
-
项目类别:
-
资助金额:$9.75万
-
财政年份:2021
-
负责人:Jose A Cancelas
-
依托单位:
Gene Delivery Core
-
批准号:10458594
-
项目类别:
-
资助金额:$9.75万
-
财政年份:2021
-
负责人:Jose A Cancelas
-
依托单位:
Targeted Inhibition in Leukemia
-
批准号:10652352
-
项目类别:
-
资助金额:$49.15万
-
财政年份:2020
-
负责人:Jose A Cancelas
-
依托单位:
Targeted Inhibition in Leukemia
-
批准号:10212981
-
项目类别:
-
资助金额:$46.56万
-
财政年份:2020
-
负责人:Jose A Cancelas
-
依托单位:
Mitochondria mediated intercellular metabolic coupling in bone marrow regeneration
-
批准号:10198919
-
项目类别:
-
资助金额:$27.98万
-
财政年份:2020
-
负责人:Jose A Cancelas
-
依托单位:
Targeted Inhibition in Leukemia
-
批准号:9914382
-
项目类别:
-
资助金额:$50.25万
-
财政年份:2020
-
负责人:Jose A Cancelas
-
依托单位:
Mitochondria mediated intercellular metabolic coupling in bone marrow regeneration
-
批准号:9916336
-
项目类别:
-
资助金额:$27.98万
-
财政年份:2020
-
负责人:Jose A Cancelas
-
依托单位:
Mitochondria mediated intercellular metabolic coupling in bone marrow regeneration
-
批准号:10400955
-
项目类别:
-
资助金额:$27.98万
-
财政年份:2020
-
负责人:Jose A Cancelas
-
依托单位:
Targeted Inhibition in Leukemia
-
批准号:10428571
-
项目类别:
-
资助金额:$49.15万
-
财政年份:2020
-
负责人:Jose A Cancelas
-
依托单位:
Small molecules targeting RhoA for platelet cold storage in cancer care
-
批准号:9900068
-
项目类别:
-
资助金额:$63.55万
-
财政年份:2019
-
负责人:Jose A Cancelas
-
依托单位:
Small molecules targeting RhoA for platelet cold storage in cancer care
-
批准号:9763067
-
项目类别:
-
资助金额:$63.55万
-
财政年份:2019
-
负责人:Jose A Cancelas
-
依托单位:
Small molecules targeting RhoA for platelet cold storage in cancer care
-
批准号:10363724
-
项目类别:
-
资助金额:$63.55万
-
财政年份:2019
-
负责人:Jose A Cancelas
-
依托单位:
Disseminating Curative Biological Therapies for Rare Pediatric Diseases
-
批准号:9762236
-
项目类别:
-
资助金额:$135.8万
-
财政年份:2016
-
负责人:Jose A Cancelas
-
依托单位:
G-CSF in Human Severe Congenital Neutropenia
-
批准号:9099909
-
项目类别:
-
资助金额:$30.81万
-
财政年份:2015
-
负责人:Jose A Cancelas
-
依托单位:
Rho GTPase inhibitors for refrigerated platelet storage
-
批准号:8712846
-
项目类别:
-
资助金额:$22.47万
-
财政年份:2014
-
负责人:Jose A Cancelas
-
依托单位:
Rho GTPase inhibitor for refrigerated platelet storage
-
批准号:10758680
-
项目类别:
-
资助金额:$85.87万
-
财政年份:2014
-
负责人:Jose A Cancelas
-
依托单位:
Improving hematopoietic stem cell mobilization by the EGFR inhibitor Erlotinib
-
批准号:8247250
-
项目类别:
-
资助金额:$39.03万
-
财政年份:2012
-
负责人:Jose A Cancelas
-
依托单位:
海外基金